Biopharmaceutical aspects and implications of excipient variability in drug product performance.

TL;DR: In vivo evidence for the improved BA of water-insoluble drugs using liposomes is focused on to resolve doubts raised concerning liposomal oral delivery and insight is provided by highlighting the approaches used for in vivo achievements.

TL;DR: In this article, the authors proposed a method to solve the problem of the lack of resources in the South Korean market by using the concept of "social media" and "social networks".

TL;DR: Improved formulations utilising non-conventional bio-based excipients to improve tablet release rates indicated that tablets containing Alcell lignin have quicker release, faster disintegration times and higher tablet hardness for all samples with differing process parameters.

TL;DR: Results suggest that carboxylated lignin tablets had the highest drug release, which is linked to their faster disintegration and lower tablet hardness, and its influence on paracetamol control release behavior at varying pH.

TL;DR: Implementation of QbD will enable transformation of the chemistry, manufacturing, and controls (CMC) review of abbreviated new drug applications into a science-based pharmaceutical quality assessment.

TL;DR: As the pharmaceutical industry moves toward the implementation of pharmaceutical QbD, a common terminology, understanding of concepts and expectations are necessary and this understanding will facilitate better communication between those involved in risk-based drug development and drug application review.

TL;DR: The Food and Drug Administration (FDA) regulates pharmaceutical drug products to ensure a continuous supply of high-quality drugs in the USA as mentioned in this paper, where the FDA supports the implementation of continuous manufacturing using science-and risk-based approaches.